Related references
Note: Only part of the references are listed.A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
Yan G. Ni et al.
JOURNAL OF LIPID RESEARCH (2011)
An update on the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE-IT) design
Robert M. Califf et al.
AMERICAN HEART JOURNAL (2010)
Effect of Mipomersen, an Apolipoprotein B Synthesis Inhibitor, on Low-Density Lipoprotein Cholesterol in Patients With Familial Hypercholesterolemia
Fatima Akdim et al.
AMERICAN JOURNAL OF CARDIOLOGY (2010)
Efficacy and Safety of Fenofibric Acid Co-Administered with Low- or Moderate-Dose Statin in Patients with Mixed Dyslipidemia and Type 2 Diabetes Mellitus Results of a Pooled Subgroup Analysis from Three Randomized, Controlled, Double-Blind Trials
Peter H. Jones et al.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS (2010)
Do structural differences in statins correlate with clinical efficacy? Lorenzo Arnaboldi and Alberto Corsini
Lorenzo Arnaboldi et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Lipid lowering with thyroid hormone and thyromimetics
Bo Angelin et al.
CURRENT OPINION IN LIPIDOLOGY (2010)
Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
Marianne Abifadel et al.
EXPERT OPINION ON THERAPEUTIC PATENTS (2010)
A new method for measurement of total plasma PCSK9: clinical applications
Genevieve Dubuc et al.
JOURNAL OF LIPID RESEARCH (2010)
Efficacy and Safety of Mipomersen, an Antisense Inhibitor of Apolipoprotein B, in Hypercholesterolemic Subjects Receiving Stable Statin Therapy
Fatima Akdim et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2010)
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Frederick J. Raal et al.
LANCET (2010)
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial
Paul M. Ridker et al.
LANCET (2010)
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Paul W. Ladenson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
The ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus.
Lukasz Januszkiewicz
KARDIOLOGIA POLSKA (2010)
A Locked Nucleic Acid Antisense Oligonucleotide (LNA) Silences PCSK9 and Enhances LDLR Expression In Vitro and In Vivo
Nidhi Gupta et al.
PLOS ONE (2010)
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
Henry N. Ginsberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Efficacy and Safety of ABT-335 (Fenofibric Acid) in Combination With Atorvastatin in Patients With Mixed Dyslipidemia
Anne C. Goldberg et al.
AMERICAN JOURNAL OF CARDIOLOGY (2009)
Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100
Rosie Z. Yu et al.
BIOCHEMICAL PHARMACOLOGY (2009)
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult-2009 recommendations
Jacques Genest et al.
CANADIAN JOURNAL OF CARDIOLOGY (2009)
Lack of Pharmacokinetic Interaction of Mipomersen Sodium (ISIS 301012), a 2 '-O-Methoxyethyl Modified Antisense Oligonucleotide Targeting Apolipoprotein B-100 Messenger RNA, with Simvastatin and Ezetimibe
Rosie Z. Yu et al.
CLINICAL PHARMACOKINETICS (2009)
What's the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?
Harold E. Bays et al.
CURRENT OPINION IN LIPIDOLOGY (2009)
Lowering Low-Density Lipoprotein Cholesterol: Statins, Ezetimibe, Bile Acid Sequestrants, and Combinations: Comparative Efficacy and Safety
Runhua Hou et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2009)
Colesevelam hydrochloride: usefulness of a specifically engineered bile acid sequestrant for lowering LDL-cholesterol
Alberto Corsini et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2009)
Major Lipids, Apolipoproteins, and Risk of Vascular Disease
The Emerging Risk Factors Collaboration*
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2009)
Function and distribution of circulating human PCSK9 expressed extrahepatically in transgenic mice
Yi Luo et al.
JOURNAL OF LIPID RESEARCH (2009)
Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes
John D. Baxter et al.
NATURE REVIEWS DRUG DISCOVERY (2009)
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Bengt C. Fellstroem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Reply to Chesson et al.: Carbon stable isotopes in beef differ distinctly between corporations
Hope Jahren et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
Joyce C. Y. Chan et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Antisense oligonucleotide directed to human apolipoprotein B-100 reduces lipoprotein(a) levels and oxidized phospholipids on human apolipoprotein B-100 particles in lipoprotein(a) transgenic mice
Esther Merki et al.
CIRCULATION (2008)
Lipoprotein management in patients with cardiometabolic risk - Consensus conference report from the American diabetes association and the American college of cardiology foundation
John D. Brunzell et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2008)
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
Luigi Tavazzi et al.
LANCET (2008)
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Paul M. Ridker et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates
Maria Frank-Kamenetsky et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia
Frederick F. Samaha et al.
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE (2008)
Molecular diagnosis of hypobetalipoproteinemia: An ENID review
Patrizia Tarugi et al.
ATHEROSCLEROSIS (2007)
Rosuvastatin in older patients with systolic heart failure
John Kjekshus et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Secreted PCSK9 promotes LDL receptor degradation independently of proteolytic activity
Jun Li et al.
BIOCHEMICAL JOURNAL (2007)
Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Michael H. Davidson et al.
CLINICAL THERAPEUTICS (2007)
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Mark J. Graham et al.
JOURNAL OF LIPID RESEARCH (2007)
Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia
James M. McKenney et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2007)
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (Results from the EXPLORER study)
Christie M. Ballantyne et al.
AMERICAN JOURNAL OF CARDIOLOGY (2007)
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Marina Cuchel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Results of the Glucose-Lowering Effect of WelChol Study (GLOWS): A randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes
Franklin J. Zieve et al.
CLINICAL THERAPEUTICS (2007)
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised openlabel, blinded endpoint analysis
Mitsuhiro Yokoyama et al.
LANCET (2007)
European guidelines on cardiovascular disease prevention in clinical practice: Full text
Ian Graham et al.
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION (2007)
Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B
John J. P. Kastelein et al.
CIRCULATION (2006)
AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update - Endorsed by the National Heart, Lung, and Blood Institute
Sidney C. Smith et al.
CIRCULATION (2006)
Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy
KE Berge et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2006)
Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia
HE Bays et al.
AMERICAN JOURNAL OF CARDIOLOGY (2006)
Sequence variations in PCSK9, low LDL, and protection against coronary heart disease
JC Cohen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
A spectrum of PCSK9 Alleles contributes to plasma levels of low-density lipoprotein cholesterol
IK Kotowski et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions
MH Davidson
EXPERT OPINION ON DRUG SAFETY (2006)
Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote
Zhenze Zhao et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2006)
High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial
TR Pedersen et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial
A Keech et al.
LANCET (2005)
Hepatic and cardiovascular consequences of familial hypobetalipoproteinemia
RR Sankatsing et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2005)
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review
LA Carlson
JOURNAL OF INTERNAL MEDICINE (2005)
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
C Wanner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
An apolipoprotein B antisense oligonucleotide lowers LDL cholesterol in hyperlipidemic mice without causing hepatic steatosis
RM Crooke et al.
JOURNAL OF LIPID RESEARCH (2005)
Intensive lipid lowering with atorvastatin in patients with stable coronary disease
JC LaRosa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9
C Jonathan et al.
NATURE GENETICS (2005)
Intensive versus moderate lipid lowering with statins after acute coronary syndromes
CP Cannon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Effects of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: Additional results from the STELLAR trial
PH Jones et al.
CLINICAL THERAPEUTICS (2004)
Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia
G Dubuc et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2004)
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines
SM Grundy et al.
CIRCULATION (2004)
Locked nucleic acid: A potent nucleic acid analog in therapeutics and biotechnology
JS Jepsen et al.
OLIGONUCLEOTIDES (2004)
Progress in antisense technology
ST Crooke
ANNUAL REVIEW OF MEDICINE (2004)
Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype
KN Maxwell et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvalstaltin, and pravastatin across doses (STELLAR* trial)
PH Jones et al.
AMERICAN JOURNAL OF CARDIOLOGY (2003)
Monogenic hypercholesterolemia: new insights in pathogenesis and treatment
DJ Rader et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
M Abifadel et al.
NATURE GENETICS (2003)
Blocking microsomal triglyceride transfer protein interferes with apoB secretion without causing retention or stress in the ER
W Liao et al.
JOURNAL OF LIPID RESEARCH (2003)
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA):: a multicentre randomised controlled trial
PS Sever et al.
LANCET (2003)
Antisense technologies - Improvement through novel chemical modifications
J Kurreck
EUROPEAN JOURNAL OF BIOCHEMISTRY (2003)
Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care - The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)
CD Furberg et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
J Shepherd et al.
LANCET (2002)
Inhibition of intestinal cholesterol absorption by ezetimibe in humans
T Sudhop et al.
CIRCULATION (2002)
ACC/AHA/NHLBI clinical advisory on the use and safety of statins
RC Pasternak et al.
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY (2002)
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo-controlled trial
R Collins et al.
LANCET (2002)
Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions - The Atherosclerosis Risk in Communities (ARIC) Study
AR Sharrett et al.
CIRCULATION (2001)
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells
SM Elbashir et al.
NATURE (2001)
Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
JI Cleeman et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease - The bezafibrate infarction prevention (BIP) study
Z Schlesinger et al.
CIRCULATION (2000)
Share Paper
